Kathryn Fekete, D.O. Pediatrics Medicare: Medicare Enrolled Practice Location: 3073 White Mountain Hwy, North Conway, NH 03860 Phone: 603-356-3337 |
Wenda Saunders, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 3073 White Mountain Hwy, North Conway, NH 03860 Phone: 603-356-5472 Fax: 603-356-9647 |
Katherine Elizabeth Mcgrath, DO Pediatrics Medicare: Medicare Enrolled Practice Location: 3073 White Mountain Hwy, North Conway, NH 03860 Phone: 603-356-5461 |
Dr. Charlotte Helvie, M.D. Pediatrics Medicare: Medicare Enrolled Practice Location: 3073 White Mountain Hwy, North Conway, NH 03860 Phone: 603-356-5461 |
News Archive
In advance of National Infant Immunization Week, observed April 23-30, Californians for Patient Care reminds parents there are affordable immunizations available for their infants in their communities.
One of the main indicators for determining the activity of a tumour or cancer is cell division. Cancer cells divide more than other types and the genes and molecules involved in the process of division are, often, targets for identifying and treating certain types of cancer.
The American Association of Homes and Services for the Aging (AAHSA) commends Senator Reid (D-Nev.) for his leadership on ensuring that the Community Living and Supportive Services (CLASS) Plan provisions are included in the Senate's health reform bill.
How can an active principle be delivered in a controlled way? Until now, there was no obvious answer to this question. Now however, researchers at the CNRS Paul Pascal Research Center in Bordeaux have designed smart capsules that are able to release their contents on demand, simply by raising the temperature. Described in an article published on 2 February 2010 in the journal Langmuir, this novel system has just been patented. It opens up the way to many applications in a large number of fields such as food, perfumes and agriculture, for instance to deliver pesticides above a specific temperature.
Theraclone Sciences, Inc., a therapeutic antibody discovery and development company, today announced positive top-line data from its Phase 1 trial of TCN-032, a broadly protective, fully human monoclonal antibody, being developed for the treatment of influenza A infections.
› Verified 8 days ago